



English Version



Spanish version

# Clinical characterization and outcomes of a cohort of colombian patients with AL Amyloidosis

## Caracterización clínica y desenlaces de una cohorte de pacientes colombianos con amiloidosis AL

Jorge Andrés Lacouture Fierro<sup>1,2</sup>  Daniel Andrés Ribero Vargas<sup>3,4</sup>  Juanita Sánchez Cano<sup>5</sup>  
 Lina María Gaviria Jaramillo<sup>2,6</sup>  Oliver Gerardo Perilla Suarez<sup>2,6</sup>  Kenny Mauricio Galvez  
Cárdenas<sup>7</sup>  Sigifredo Ospina Ospina<sup>8</sup> 

1 Hospital San Vicente Fundación Rionegro, Colombia. 2 Universidad de Antioquia, Sección de Hematología Clínica, Departamento de Medicina interna, Facultad de Medicina, Medellín, Colombia. 3 Universidad de Antioquia, Departamento de Medicina interna, Facultad de medicina, Medellín, Colombia. 4 Hospital Alma Mater de Antioquia, Departamento de Medicina Interna, Medellín, Colombia. 5 Hospital Pablo Tobón Uribe; Medellín; Colombia. 6 Hospital San Vicente Fundación Medellín, Departamento de Hematología, Medellín, Colombia. 7 Hospital Pablo Tobón Uribe, Departamento de Hematología, Medellín, Colombia. 8 Universidad de Antioquia, Instituto de Investigaciones Médicas, Facultad de Medicina, Medellín, Colombia.



OPEN ACCESS

**Citation:** Lacouture FJA, Ribero VDA, Sánchez CJ, Gaviria JLM, Perilla SOG, Galvez CKM, Ospina OS. **Clinical characterization and outcomes of a cohort of colombian patients with AL Amyloidosis.** Colomb Méd (Cali), 2023; 54(3):e2025667. <http://doi.org/10.25100/cm.v54i3.5667>

**Received:** 04 jul 2023

**Revised:** 30 jul 2023

**Accepted :** 24 sep 2023

**Published:** 30 sep 2023

### Keywords:

Amyloidosis; bortezomib; lenalidomida; transplantation; immunoglobulin light-chain; daratumumab; amyloidogenic proteins; plasma cells; multiple myeloma; hematopoietic stem cell transplantation response.

### Palabras clave:

Amiloidosis; bortezomib; lenalidomida; trasplante; cadenas ligeras de inmunoglobulinas; daratumumab; proteínas amiloidogénicas; células plasmáticas; mieloma múltiple; respuesta al trasplante autólogo de progenitores hematopoyéticos.

## Abstract

### Background:

Amyloid light chain (AL) amyloidosis is characterized by amyloid fibril deposition derived from monoclonal immunoglobulin light chains, resulting in multiorgan dysfunction. Limited data exist on the clinical features of AL amyloidosis.

### Objective:

This study aims to describe the clinical characteristics, treatments, and outcomes in Colombian patients with AL amyloidosis.

### Methods:

A retrospective descriptive study was conducted at three high-complexity centers in Medellín, Colombia. Adults with AL amyloidosis diagnosed between 2012 and 2022 were included. Clinical, laboratory, histological, treatment, and survival data were analyzed.

### Results:

The study included 63 patients. Renal involvement was most prevalent (66%), followed by cardiac involvement (61%). Multiorgan involvement occurred in 61% of patients. Amyloid deposition was most commonly detected in renal biopsy (40%). Bortezomib-based therapy was used in 68%, and 23.8% received high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HDCT-ASCT). Hematological response was observed in 95% of patients with available data. Cardiac and renal organ responses were 15% and 14%, respectively. Median overall survival was 45.1 months (95% CI: 22.2-63.8). In multivariate analysis, cardiac involvement was significantly associated with inferior overall survival (HR 3.27; 95% CI: 1.23-8.73; p=0.018), HDCT-ASCT had a non-significant trend towards improved overall survival (HR 0.25; 95% CI: 0.06-1.09; p=0.065).

Copyright: © 2023 Universidad del Valle



**Conflict of interest:**

All authors have declared no conflicts of interest

**Corresponding author:**

Jorge Andres Lacouture Fierro.  
Hospital San Vicente Fundación  
Rionegro, Rionegro, Colombia.

Email: [jorge.lacouture@sanvicentefundacion.com](mailto:jorge.lacouture@sanvicentefundacion.com)

## Conclusions:

In this study of Colombian patients with AL amyloidosis, renal involvement was more frequent than cardiac involvement. Overall survival and multiorgan involvement were consistent with data from other regions of the world. Multivariate analysis identified cardiac involvement and HDCT-AHCT as possible prognostic factors.

## Resumen

### Antecedentes:

La amiloidosis por amiloide de cadenas ligeras (AL) se caracteriza por el depósito de fibrillas amiloides derivadas de cadenas ligeras de inmunoglobulinas monoclonales, lo que resulta en disfunción multiorgánica. Existen datos limitados sobre las características clínicas de la amiloidosis AL.

### Objetivo:

Este estudio tiene como objetivo describir las características clínicas, tratamientos y desenlaces en pacientes colombianos con amiloidosis AL.

### Métodos:

Se llevó a cabo un estudio descriptivo retrospectivo en tres centros de alta complejidad en Medellín, Colombia. Se incluyeron adultos con diagnóstico de amiloidosis AL entre 2012 y 2022. Se analizaron datos clínicos, de laboratorio, histológicos, de tratamiento y de supervivencia.

### Resultados:

El estudio incluyó 63 pacientes. La afectación renal fue más prevalente (66%), seguida de la afectación cardíaca (61%). El 61% de los pacientes presentaron afectación multiorgánica. El depósito amiloide se detectó con mayor frecuencia en la biopsia renal (40%). El tratamiento basado en bortezomib se utilizó en el 68%, y el 23.8% recibió altas dosis de quimioterapia con trasplante autólogo de progenitores hematopoyéticos (ADQT-TAPH). Se observó respuesta hematológica en el 95% de los pacientes con datos disponibles. La respuesta de órgano cardíaca y renal fue del 15% y 14%, respectivamente. La mediana de la supervivencia global fue de 45.1 meses (IC del 95%: 22.2-63.8). En el análisis multivariado, la afectación cardíaca se asoció significativamente con una supervivencia global inferior (HR 3.27; IC del 95%: 1.23-8.73; p=0.018), ADQT-TAPH mostró una tendencia no significativa hacia una mejora en la supervivencia global (HR 0.25; IC 95%: 0.06-1.09; p=0.065).

### Conclusiones:

En este estudio de pacientes colombianos con amiloidosis AL, la afectación renal fue más frecuente que la afectación cardíaca. La supervivencia global y la afectación multiorgánica fueron consistentes con datos de otras regiones del mundo. El análisis multivariado identificó la afectación cardíaca y ADQT-TAPH como posibles factores pronósticos.

## Introduction

Primary or amyloid light chain (AL) amyloidosis is the most common form of systemic amyloidosis<sup>1</sup>. This disease originates from a clone of plasma cells or, less frequently, from

## Remark

### 1) ¿Why was this study conducted?

To describe the clinical characteristics, treatment patterns, and outcomes of patients with AL amyloidosis in the Colombian population through a retrospective analysis in three highly specialized centers in Medellín, Colombia.

### 2) ¿What were the most relevant results of the study?

The study found a higher frequency of renal involvement compared to cardiac involvement. Additionally, the frequency of multiorgan involvement was similar to other regions, such as Europe and Asia. The overall survival rate observed in this study was comparable to that reported in a recent European publication. The multivariate analysis conducted in the study identified cardiac involvement and consolidation with HDCT-AHCT as potential prognostic factors.

### 3) ¿What do these results contribute?

This study reports the characteristics and outcomes of Colombian patients with AL amyloidosis, identifies potential prognostic factors in our population and provides a basis for designing future studies with a broader scope.

a low-grade lymphoma such as chronic lymphocytic leukemia (CLL), lymphoplasmacytic lymphoma, or marginal zone lymphoma, capable of secreting monoclonal immunoglobulin light chains with unstable folding due to mutations in their variable region <sup>2</sup>. In 80% of cases, the compromised light chain is the lambda chain due to a higher intrinsic amyloidogenic predisposition than the kappa chain <sup>3,4</sup>. This amyloidogenic protein activates the formation, aggregation, and stabilization of insoluble amyloid fibrils that exhibit a high affinity for Congo red staining, characteristic of this disease <sup>3</sup>. The presence of amyloid deposits in different tissues leads to organ dysfunction mediated by proteotoxicity and replacement of the typical architecture, eventually resulting in systemic signs and symptoms <sup>5,6</sup>.

AL amyloidosis is a rare and challenging-to-diagnose disease, resulting in limited published data regarding its global epidemiology and clinical characteristics <sup>7,8</sup>. Recently updated data from a patient cohort in Olmsted, Minnesota, estimate an incidence of 8.9 to 12 cases per million person-years <sup>9,10</sup>; data from other regions of the world estimate an incidence of 3 to 12 cases per million person-years <sup>11-13</sup>. A recently published systematic review of the literature used published data from North America, South America, Europe, and Asia to evaluate the global epidemiology of AL amyloidosis, estimating an incidence and 20-year prevalence rate of 10.44 and 51 cases per million person-years, respectively <sup>14</sup>.

Except for the central nervous system, monoclonal immunoglobulin light chains can deposit virtually in any tissue, leading to a wide range of clinical manifestations and organ involvement, including the heart, kidneys, liver, soft tissues, peripheral nervous system, among others, which are also the main prognostic markers <sup>8,15,16</sup>.

The current treatment of AL amyloidosis primarily focuses on suppressing the underlying malignant neoplasm to reduce the production of amyloidogenic light chains <sup>2</sup>. There are no approved therapies for the treatment of AL amyloidosis, so the therapy for this disease has been heterogeneous, based on adapted combinations of treatments for multiple myeloma or low-grade lymphomas <sup>17</sup>, including regimens such as MDex (melphalan and dexamethasone), VMD (bortezomib, melphalan, and dexamethasone), CyBorD (cyclophosphamide,

bortezomib, and dexamethasone)<sup>18,19</sup>, and consolidation of response with high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HDCT-AHCT) in eligible patients<sup>20</sup>. Recently published data demonstrated promising results with the addition of Daratumumab to the CyBorD regimen, achieving better response rates and progression-free survival than CyBorD<sup>21</sup>. The prognosis of AL amyloidosis is influenced by multiple factors, including the severity of cardiac involvement, which has been established as the primary determinant of survival<sup>2,22,23</sup>, coexistence with other neoplasms such as multiple myeloma<sup>24</sup>, depth of hematological response<sup>25</sup>, among others.

Although some studies report data from Latin America, there is a lack of information about Colombian patients. This study aims to describe the clinical characteristics, treatment patterns, and outcomes of patients with AL amyloidosis in the Colombian population through a retrospective analysis in three highly specialized centers in Medellín, Colombia.

## Materials and Methods

### Study Design

A retrospective study was conducted.

### Population and sample

The study population consisted of patients over 18 years of age, of both sexes, diagnosed with AL amyloidosis, who had been seen as outpatients or hospitalized for this condition at Hospital Universitario San Vicente Fundación de Medellín, Hospital San Vicente Fundación de Rionegro, or Hospital Pablo Tobon Uribe between January 2012 and December 2022.

We included all patients who met the inclusion criteria during the study period, excluding only those who did not have information on the variables of interest.

The diagnosis of AL amyloidosis required histological demonstration of amyloid deposits by positive Congo red staining and apple-green birefringence under polarized light, associated with the presence of monoclonal gammopathy identified by serum/urine immunofixation, an abnormal kappa/lambda ratio indicating an excess of light chains, or the presence of clonal plasma cells in bone marrow biopsy<sup>7,21</sup>. Other types of amyloidosis (AA amyloidosis, transthyretin amyloidosis, localized amyloidosis, hereditary amyloidosis, etc.) were excluded. Organ involvement classification, organ response, and hematological response were defined according to the criteria of the 10<sup>th</sup> International Symposium on Amyloid and Amyloidosis published in 2005<sup>26</sup> and the guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis published in 2012<sup>27</sup>.

### Variables

Demographic, clinical, laboratory, histological, functional status, treatment, and overall survival variables were evaluated. Univariate analysis was performed to determine the potential effect of associated neoplasms, renal involvement, cardiac involvement, and HDCT-AHCT on the overall survival of the evaluated population, and multivariate analysis was conducted to adjust for possible confounding variables. Clinical information was retrospectively obtained from electronic medical records and independently reviewed by six physicians.

### Statistical Analysis

For categorical variables, absolute and relative frequency distributions were used for each category. For numerical variables, measures of central tendency such as mean with standard deviation or median with interquartile range were used.

Overall survival was analyzed using the Kaplan-Meier model with median survival and 95% confidence intervals (CI). Cox regression analysis assessed associated factors, verifying the proportional hazards assumption. Observed and adjusted hazard ratios (HR) along with 95% CI and p-values were estimated. Variables with  $p < 0.25$  in the multivariate analysis were included in the adjustment. Through post hoc analysis, it was established, with an alpha of 0.05, that the statistical power is greater than or equal to 0.80 for  $HR \geq 2.7$  or  $HR: \leq 0.31$ .

### **Ethical considerations**

The Research Directorate and the Ethics Committee of Hospital Universitario San Vicente Fundación de Medellín, Hospital San Vicente Fundación de Rionegro, and Hospital Pablo Tobon Uribe approved this study. Data confidentiality was ensured to prevent patient identification during the publication stages.

## **Results**

### **Patient Characteristics**

This study included 63 patients with AL amyloidosis, with demographic, clinical, histological, treatment, and survival outcomes evaluated. Table 1 provides details of the analyzed clinical and laboratory characteristics.

The mean age of the patients was 60 years (SD: 14.2), ranging from 34 to 87 years. Thirty-six (57%) patients were male. Forty-three (68%) patients had an ECOG performance status of  $\leq 2$ . According to the criteria of the International Symposium on Amyloid and Amyloidosis (26), 42 (66%) patients had renal involvement, followed by cardiac involvement (61%), peripheral nervous system involvement (34%), soft tissue involvement (26%), hepatic involvement (25%), pulmonary involvement (12.6%), and gastrointestinal involvement (9.5%). The majority of patients (61%) had involvement of two or more organs. Among the patients with renal involvement, 22 (52%) had nephrotic-range proteinuria ( $\geq 3500$  mg/24 hours), representing 34% of all evaluated patients. Ten (43%) cardiac-involved patients had brain natriuretic peptide (BNP) levels  $\geq 700$  ng/L.

### **Histological and laboratory findings**

Information on histological results was obtained for 57 (90%) patients, including 63 biopsies taken from different tissues. Among the analyzed patients with available histological results, amyloid deposition was most frequently detected in renal biopsies (40%), followed by abdominal fat biopsy (17%), bone marrow biopsy (12%), myocardium (8%), liver (8%), lymph node (5%), gastrointestinal tract (5%), skin (5%), minor salivary gland (3%), and lung (3%).

Regarding laboratory results during the initial diagnostic approach, 16 (25%) patients had anemia, 6 (9.5%) had thrombocytosis, nine patients (14%) presented with creatinine greater than 1.5 mg/dL, and 11 patients (22.9%) had a GFR  $< 50$  ml/min/1.73 m<sup>2</sup> at the time of diagnosis. In most cases, the involved immunoglobulin light chain was the lambda chain (71%), while the kappa isotype was present in 13 patients (20%). Out of 33 patients with information on serum free light chain concentration was obtained, 29 (87%) had an abnormal kappa/lambda ratio. The distribution of immunoglobulin heavy chains was as follows: serum immunofixation by electrophoresis was positive in 58 patients (90%), including 19 (30%) patients with IgG, 9 (14%) with IgA, 2 (3%) with IgM, 1 (1.5%) with IgD, and 27 (42%) patients with isolated immunoglobulin light chain involvement.

Thirty-eight patients (60%) had another neoplasm associated with AL amyloidosis, 37 (58.5%) had multiple myeloma, and 1 (1.5%) had chronic lymphocytic leukemia. The average percentage of plasma cell infiltration in the bone marrow was 19% (SD: 22.3), and 33 (52%) patients had 10% or more infiltration of the bone marrow by plasma cells.

**Table 1.** Demographic and Clinical Characteristics of AL amyloidosis patients

Characteristics	Number of patients (%)
Sex	
Male	36 (57)
<b>Age (years)</b>	
Mean (Range)	60 (34-87)
<b>ECOG</b>	
0	4 (6.0)
1	25 (40)
2	14 (22)
3	7 (11)
No data	13 (21)
Thrombocytosis (PLTs >450,000/mm <sup>3</sup> )	6 (9.5)
Anemia (Hb <10 gr/dL)	16 (25)
Creatinine >1.5 mg/dL	9 (14) <sup>a</sup>
Mean eGFR by CKD-EPI (ml/min/1.73 m <sup>2</sup> )	73 (SD: 29.5) <sup>a</sup>
eGFR <50 ml/min/1.73 m <sup>2</sup>	11 (22.9) <sup>a</sup>
<b>Involved light chain</b>	
Lambda	45 (71)
Kappa	13 (21)
No data	5 (8.0)
<b>Involved heavy chain</b>	
IgG	19 (30.0)
IgA	9 (14.0)
IgM	2 (3.0)
IgD	1 (1.5)
No heavy chain involvement	27 (42.0)
No data	6 (9.5)
<b>Associated neoplasm</b>	
Multiple mieloma	37 (58.0)
Chronic lymphocytic leukemia	1 (1.5)
None	25 (40.0)
Mean plasma cell infiltration in bone marrow	19% (SD: 22.3)
Plasma cell infiltration in bone marrow ≥10%	33 (52)
Abnormal kappa/lambda ratio (<0.26 or >1.65)	29 (87) <sup>b</sup>
Mean dFLC at admission (mg/L)	9,553 (SD: 17,519)
Mean proteinuria at admission (mg/24h)	5,444 (SD: 6,334) <sup>c</sup>
Nephrotic range proteinuria (≥3,500 mg/24 hours)	22 (49)
Mean BNP at admission (ng/L)	663 (SD: 619) <sup>d</sup>
BNP >81 ng/L	20 (86)
BNP >700 ng/L	10 (43)
<b>Organ involvement</b>	
Renal	42 (66.0)
Cardiac	39 (61.0)
Peripheral nervous system	22 (34.0)
Soft tissues	17 (26.0)
Hepatic	16 (25.0)
Pulmonary	8 (12.6)
Gastrointestinal	6 (9.5)
Two or more organs	39 (61)

GFR = glomerular filtration rate. dFLC = involved-uninvolved light chain difference. SD= standard deviation. <sup>a</sup>Information available in 48 patients. <sup>b</sup>Information available in 33 patients. <sup>c</sup>Information available in 45 patients. <sup>d</sup>Information available in 23 patients.

### Treatment, response and, survival

The study population was treated at different healthcare centers over ten years, using various treatment regimens, detailed in Table 2. Bortezomib-based therapies (VCD, VD, and Dara-VCD) were the most commonly used (68%), followed by combinations with immunomodulatory drugs such as thalidomide or lenalidomide (14%), and therapies based on alkylating agents such as melphalan or cyclophosphamide (9%); five (8%) patients did not receive induction therapy, and 15 (23.8%) patients received high-dose chemotherapy with autologous stem cell transplantation (HDCT-AHCT) after induction therapy.

Hematologic response information was obtained for 21 patients. Hematologic response was achieved in 20 patients with first-line treatment, of which 10 achieved a complete hematologic response,

**Table 2.** First-line Treatment Regimens and consolidation with HDCT-AHCT for Patients with AL Amyloidosis

Regimen	Number of patients (%)
VCD, bortezomib, cyclophosphamide, and dexamethasone	37 (59)
VD, bortezomib and dexamethasone	5 (8.0)
Daratumumab-VCD, daratumumab + bortezomib, cyclophosphamide, and dexamethasone	1 (1.6)
DRD, daratumumab, lenalidomide, and dexamethasone	1 (1.6)
VRD, bortezomib, lenalidomide, and dexamethasone	2 (3.1)
VTD, bortezomib, thalidomide, and dexamethasone	1 (1.6)
MDT, melphalan, dexamethasone, and thalidomide	3 (4.7)
CTD, cyclophosphamide, thalidomide, and dexamethasone	2 (3.1)
Mdex, melphalan and dexamethasone	2 (3.1)
MDV, melphalan, dexamethasone, and vincristine	1 (1.6)
CD, cyclophosphamide, and dexamethasone	3 (4.7)
None	5 (8.0)
HDCT-AHCT, high-dose chemotherapy followed by autologous hematopoietic cell transplantation.	15 (23.8)

3 achieved very good partial response, 7 achieved a partial response, and 1 patient experienced progression during treatment. Information regarding hematologic response was unavailable for 42 (66%) patients. Organ response was observed in 6 (15%) of 39 patients with cardiac involvement, 6 (14%) of 42 patients with renal involvement, and 1 (6%) of 16 patients with hepatic involvement.

The median overall survival of the studied population was 45.1 months (95% CI: 22.2-63.8) (Figure 1), with an average follow-up of 24.7 months at the last follow-up on March 9, 2023. The effect of various analyzed factors on survival is shown in Table 3. Cardiac involvement was significantly associated with inferior overall survival (HR, 3.27; 95% CI: 1.23-8.73;  $p=0.018$ ) (Figure 2), while renal involvement (HR: 1.84; 95% CI: 0.65-5.19;  $p=0.248$ ) or the presence of another associated neoplasm (HR: 0.98; 95% CI: 0.49-1.97;  $p=0.956$ ) did not have a significant impact on the prognosis of the evaluated population. Patients who received HDCT-AHCT showed a non-significant trend (HR: 0.25; 95% CI: 0.06-1.09;  $p=0.065$ ) towards improved overall survival.

Median overall survival: 45.1 months (95% CI: 22.2-63.8) Abbreviations: HDCT-AHCT = high-dose chemotherapy followed by autologous hematopoietic cell transplantation.


## Discussion

A retrospective analysis was conducted on patients with AL amyloidosis treated at different centers in Medellín, Colombia, to define their characteristics and outcomes, aiming to enrich


**Table 3.** Effect of clinical characteristics on overall survival

Characteristics	Univariate				Multivariate			
	HR	p-value	IC95%		HR	p-value	IC95%	
<b>Cardiac involvement</b>								
Yes	3.47	0.004	1.48	8.14	3.27	0.018	1.23	8.73
No	1.00				1			
<b>Renal involvement</b>								
Yes	1.05	0.927	0.40	2.77	1.84	0.248	0.65	5.19
No	1.00				1			
<b>Associated neoplasm</b>								
Yes	0.98	0.956	0.49	1.97				
No	1							
<b>Sex</b>								
Male	1.04	0.906	0.53	2.05				
Female	1.00							
Age at diagnosis	1.01	0.685	0.98	1.04				
<b>Intervention HDCT-AHCT</b>								
Yes	0.15	0.0114	0.04	0.65	0.25	0.065	0.06	1.09
No	1.00				1			

Median overall survival: 45.1 months (95% CI: 22.2-63.8) Abbreviations: HDCT-AHCT = high-dose chemotherapy followed by autologous hematopoietic cell transplantation.



**Figure 1.** Overall survival of the analyzed patients with AL amyloidosis



**Figure 2.** Survival of patients diagnosed with AL amyloidosis with and without cardiac involvement.

the available information on the disease in our region. The average age at the time of diagnosis in the studied population was 60 years, like what has been observed in Latin American cohorts<sup>28,29</sup>, North American population<sup>30</sup>, and recent data from European countries<sup>14,17</sup>, among other regions of the world<sup>30,31</sup>.

AL amyloidosis can be associated with other neoplasms derived from plasma cells or B lymphocytes<sup>2</sup>; in our study, most patients (58%) had multiple myeloma associated with AL amyloidosis, a higher proportion compared to the results reported by Kourelis et al.<sup>24</sup>, who reported a multiple myeloma frequency of 46% in their cohort of patients with AL amyloidosis. In the mentioned study, patients with AL amyloidosis and multiple myeloma had lower overall survival than patients with AL amyloidosis without associated neoplasm, but this effect on prognosis was not observed in the univariate analysis of our study.

Organ involvement, particularly cardiac involvement, and its severity, is the main determinant of prognosis in patients with AL amyloidosis<sup>2,23</sup>. The frequency of multiorgan involvement in the analyzed patients was 61%, like the recently published data from a European cohort by Palladini et al.<sup>17</sup>, where 63% of patients diagnosed with AL amyloidosis after 2010 had involvement of 2 or more organs. The frequency of multiorgan involvement in our study was higher than the published data by Muchtar et al.<sup>32</sup>, in North American patients, as their study considered multiorgan involvement from three or more organs.

Regarding the individual frequency of organ involvement, most of our patients (66%) had renal involvement, followed closely by cardiac involvement (61%); the published information on which of the two organs is most frequently affected in AL amyloidosis is heterogeneous. In a study published by Michael et al.<sup>30</sup>, conducted in multiple hospitals in Greece, 71% of patients had renal involvement, followed by 59% of patients with cardiac involvement. Recent studies in the Chinese population also show a higher frequency of renal involvement than cardiac involvement<sup>31</sup>. On the other hand, the aforementioned European cohort<sup>17</sup>, and the results of the study by Muchtar et al.<sup>32</sup>, reported contrary findings where cardiac involvement was more frequent than renal involvement. The recently published study by Posadas-Martinez et al.<sup>28</sup>, in Argentinean patients also showed a higher frequency of cardiac involvement. While these differences are likely due to racial differences<sup>33</sup>, it is important to note that in our setting, cardiac damage biomarkers such as BNP and N-terminal pro-B-type natriuretic peptide (NT-proBNP) have been available for a short time and in few healthcare centers; therefore, the



differences in the frequency of cardiac and renal involvement compared to other cohorts may also be explained by the underdiagnosis of cardiac involvement, which includes criteria such as elevated BNP or NT-proBNP.

Although staging systems for AL amyloidosis have been available since 2004, they are mainly based on cardiac involvement<sup>2,23,34-36</sup>, using markers of myocardial damage such as BNP, NT-proBNP, cardiac troponin T (cTnT), high-sensitivity cardiac troponin T (hs-cTnT), or cardiac troponin I (cTnI). None of the analyzed patients had validated troponin studies according to AL amyloidosis staging systems; only information on high-sensitivity cardiac troponin I (hs-cTnI) levels was available, and since there are currently no published staging scales incorporating hs-cTnI, it was not possible to stage the disease in our population. Among staging systems for AL amyloidosis, the Boston scale<sup>34</sup> includes serum BNP levels >700 ng/L as a marker of poor prognosis. Of the 23 (36%) patients in our study who had serum BNP levels at diagnosis, 43% had BNP levels >700 ng/L. Future studies should explore the impact of this marker on outcomes in patients with AL amyloidosis in Colombia.

The diagnosis of AL amyloidosis is histological and, therefore, always requires the demonstration of amyloid deposition through histopathological analysis of tissue<sup>2,37</sup>. While abdominal fat and minor salivary gland biopsies are minimally invasive alternatives with adequate sensitivity<sup>37,38</sup>, in the analyzed patients, only 20% had positive Congo red staining in one of these tissues. In comparison, amyloid deposition was demonstrated in renal biopsies in 40% of cases. This emphasizes that negative results in abdominal fat or minor salivary gland biopsies do not exclude the diagnosis of AL amyloidosis, and it is still necessary to perform biopsies of the affected organ as part of the diagnostic approach in patients suspected of having this disease.

Since the 2010s, treatment protocols based on bortezomib have become the most frequently used regimens in patients with AL amyloidosis<sup>2,17</sup>. This trend was also observed in our study population, where bortezomib-based regimens were the preferred therapy in 68% of patients, achieving a partial or better hematologic response in 20 (98%) out of 21 patients with available hematologic response information. Consolidating response with HDCT-AHCT has been reported as a superior strategy to induction chemotherapy alone<sup>20</sup>. Of the evaluated patients, 23.8% were consolidated with HDCT-AHCT, a higher proportion than in similar studies<sup>17,31,32</sup> where 4.5% to 11.4% of patients received HDCT-AHCT following induction therapy.

The evaluated population had a median survival of 45.1 months (95% CI: 22.2-63.8), similar to the data reported in previous studies conducted in other regions, where the median survival ranged from 34 to 48 months<sup>17,30-32</sup>. In the multivariate analysis, patients with cardiac involvement had lower survival, with no differences in the survival of patients with renal involvement, a finding similar to previous studies such as the work published by Sidana *et al.*<sup>22</sup>, where the median survival of patients with renal involvement was higher compared to patients with cardiac involvement or involvement of both organs. The multivariate analysis also showed a non-significant trend towards higher survival in patients consolidated with HDCT-AHCT, similar to the results reported by Gerts *et al.*<sup>20</sup>, who reported higher 3-year survival in patients treated with HDCT-AHCT following induction therapy compared to patients treated with melphalan and dexamethasone alone. However, recent studies suggest that sequential therapy with HDCT-AHCT reserved only for patients with poor response to bortezomib-based regimens could achieve similar outcomes<sup>39</sup>. Table 6 summarizes the characteristics of the present study and other similar studies previously conducted.

This study has several limitations. Firstly, due to its retrospective design, complete information on some variables, such as levels of cardiac damage biomarkers, hematologic response evaluation, and organ response, was not obtained. Although AL amyloidosis is a rare and difficult-to-diagnose disease, the small sample size of our study is an additional limitation that

**Table 4.** Characteristics of compared studies

Region	Colombia	Greece	China	United States	Argentina	Europe (post-2010)
Publication year	2024	2010	2016	2019	2022	2023
Diagnostic Methods	Congo Red + Monoclonal gammopathy	Congo Red + Monoclonal gammopathy	Congo Red + Monoclonal gammopathy	Mass spectrometry		
Number of patients	63	112	123	592	90	3,065
Age (range)	60 (34-87)	62 (38-84)	54 (34-82)	63 (56-71)	63 (50-76)	64 (29-91)
Sex	Male (57%)	Female (53%)	Male (67%)	Male (64%)	Male (54%)	Male (58%)
Anemia/Thrombocytosis	34.5%					
Renal function						
Creatinine ≥1.5	14%	25%	28% (>1.2)			
Mean glomerular filtration rate	73 (DS: 29.5)				60 +/- 51	
eGFR <50 ml/min/1.73 m <sup>2</sup>	23%			27%		
Proteinuria ≥ 3.5 g/24h	49%	39%	65%	35% (>2 g/24h)		
Monoclonal gammopathy						
Involved light chain	Lambda (71%)		Lambda (86%)	Lambda (75%)	Lambda (71%)	
Involved heavy chain	IgG (30%)		IgG (41%)	IgG (33%)		
Associated neoplasms	MM (58%)	Excluded symptomatic MM	Excluded MM	Included MM (NR)		
Infiltration by PC >10%	52%	23% (>30)	13.8% (>5)	54%	54%	
Organ involvement						
BNP >81 ng/L	86%					
BNP >700 ng/L	43%					
Renal	66%	71%	98%	53%	68%	66%
Cardiac	61%	59%	55%	76%	72%	69%
PNS	34%	38%	9.8%	24%	35%	14%
Soft tissues	26%	31%	18%		12%	20%
Hepatic	25%	18%	13%	18%	16%	13%
Pulmonary	12.6%		3.6%			0.9%
GI	9.5%	16%	72%	17%	36%	7%
2 or more	61%		91%	25% (≥3)		63%
Biopsy site	Renal (40%)		Renal (86%)			
Treatment						
Firs-line treatment	bortezomib-based (68%)	VAD or high dose steroid-based (43%)	high dose steroid-based (34%)	bortezomib-based (30%)	bortezomib-based (75%)	bortezomib-based (74%)
HDCT-AHCT	23.8%	4.5%	12%	31%	11.4%	9.8%
Response						
Cardiac	15%	6%	4%			
Renal	14%	26%	84%			
Hepatic	6%	33%	8%			
Hematologic	95% (HRC 47%)	50% (HRC 14%)	100% (HRC 44%)	84% (HRC 34%)	61% (HRC 47%)	63% (HRC 23%)
Survival analysis						
Median survival (months)	45	34	38	43	60	46
Multivariate analysis	Cardiac involvement.	Cardiac involvement. PC > 30%. Age > 65. Cr > 1.5.	Cardiac involvement. Renal involvement.	Cardiac involvement. Proteinuria > 5g/24h. Age > 65.		Complete hematologic response.

Cr= creatinine. GI= gastrointestinal. HCR= complete response. IMiD= immunomodulators. MM= multiple myeloma. NR= not reported. PC= plasma cells. PNS= peripheral nervous system. VAD= vincristine, doxorubicin, dexamethasone

may have influenced the absence of statistical associations for some of the variables evaluated in the survival analysis. This also prevents estimating multivariate models with multiple factors simultaneously. Consequently, the associations presented in this study are exploratory and necessitate confirmation through further research. The methods used for the diagnosis of AL amyloidosis in our study represent another limitation, considering the false positive and false negative rates of Congo red staining, as well as the concurrent presence of monoclonal gammopathy in patients with transthyretin amyloidosis or hereditary amyloidosis. At the same time, mass spectrometry is the gold standard for characterizing amyloid protein; it is not available in our country. However, to our knowledge, this is the first study reporting the characteristics and outcomes of Colombian patients with AL amyloidosis, providing a basis for designing future studies with a broader scope.

## Conclusion

We present the first study reporting the characteristics and outcomes of Colombian patients

with AL amyloidosis. The analyzed group of patients had a similar age distribution as reported in previous studies, with a higher frequency of renal involvement compared to cardiac involvement and a higher frequency of multiorgan involvement compared to the US population, although similar to other regions of the world, such as Europe and Asia. The proportion of patients consolidated with HDCT-AHCT was higher than reported in other studies, with a similar overall survival rate to that observed in other regions worldwide. The multivariate analysis conducted in the study identified cardiac involvement and consolidation with HDCT-AHCT as potential prognostic factors.

## References

1. Dasari S, Theis JD, Vrana JA, Rech KL, Dao LN, Howard MT, et al. Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples. *Mayo Clin Proc.* 2020; 95(9):1852-64. Doi: 10.1016/j.mayocp.2020.06.029 PMID:32861330
2. Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. *Am J Hematol.* 2022; 97(6): 818-29. Doi: 10.1002/ajh.26569 PMID:35429180
3. Merlini G, Bellotti V. Molecular Mechanisms of Amyloidosis. *New Engl J Med.* 2003; 349(6): 583-96. Doi: 10.1056/NEJMra023144 PMID:12904524
4. Merlini G. AL amyloidosis: from molecular mechanisms to targeted therapies. *Hematology.* 2017; 2017(1): 1-12. Doi: 10.1182/asheducation-2017.1.1
5. Guan J, Mishra S, Qiu Y, Shi J, Trudeau K, Las G, et al. Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. *EMBO Mol Med.* 2014; 6(11): 1493-507. Doi: 10.15252/emmm.201404190
6. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med.* 2016; 8(6): 595-608. Doi: 10.15252/emmm.201606210
7. Vaxman I, Dispenzieri A, Muchtar E, Gertz M. New developments in diagnosis, risk assessment and management in systemic amyloidosis. *Blood Rev.* 2020; 40: 100636. Doi: 10.1016/j.blre.2019.100636
8. Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. *Blood Adv.* 2018; 2(10): 1046-53. Doi: 10.1182/bloodadvances.2018016402
9. Kyle RA, Larson DR, Kurtin PJ, Kumar S, Cerhan JR, Therneau TM, et al. Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. *Mayo Clin Proc.* 2019; 94(3): 465-71. Doi: 10.1016/j.mayocp.2018.08.041
10. Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O'Fallon WM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. *Blood.* 1992; 79(7): 1817-22. Doi: 10.1182/blood.V79.7.1817.bloodjournal7971817
11. Wisniewski B, McLeod DSA, Adams R, Harvey Y, Brown I, McGuire L, et al. The epidemiology of amyloidosis in Queensland, Australia. *Br J Haematol.* 2019; 186(6): 829-36. Doi: 10.1111/bjh.16000 PMID:31148162
12. Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SDJ, et al. Systemic amyloidosis in England: an epidemiological study. *Br J Haematol.* 2013; 161(4): 525-32. Doi: 10.1111/bjh.12286
13. Duhamel S, Mohty D, Magne J, Lavergne D, Bordessoule D, Aboyans V, et al. Incidence and prevalence of light chain amyloidosis: a population-based study. *Blood.* 2017; 130(Supplement 1): 5577-5577. Doi: 10.1182/

blood.V130.Suppl\_1.5577.5577

14. Kumar N, Zhang NJ, Cherepanov D, Romanus D, Hughes M, Faller D V. Global epidemiology of amyloid light-chain amyloidosis. *Orphanet J Rare Dis.* 2022; 17(1): 278. Doi: 10.1186/s13023-022-02414-6
15. Hasib Sidiqi M, Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. *Blood Cancer J.* 2021; 11(5): 90. Doi: 10.1038/s41408-021-00483-7
16. Palladini G, Milani P, Merlini G. Novel strategies for the diagnosis and treatment of cardiac amyloidosis. *Expert Rev Cardiovasc Ther.* 2015; 13(11): 1195-211. Doi: 10.1586/14779072.2015.1093936
17. Palladini G, Schönland S, Merlini G, Milani P, Jaccard A, Bridoux F, et al. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. *Blood Cancer J.* 2023; 13(1): 19. Doi: 10.1038/s41408-023-00789-8
18. Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. *Blood.* 2015; 126(5): 612-5. Doi: 10.1182/blood-2015-01-620302
19. Kastiris E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, et al. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. *J Clin Oncol.* 2020; 38(28): 3252-60. Doi: 10.1200/JCO.20.01285
20. Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, et al. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. *Cancer.* 2016; 122(14): 2197-205. Doi: 10.1002/cncr.30051
21. Kastiris E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. *N Engl J Med.* 2021; 385(1): 46-58. Doi: 10.1056/NEJMoa2028631
22. Sidana S, Tandon N, Gertz MA, Dispenzieri A, Ramirez-Alvarado M, Murray DL, et al. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. *Br J Haematol.* 2019; 185(4): 701-7. Doi: 10.1111/bjh.15832
23. Muchtar E, Dispenzieri A, Wisniewski B, Palladini G, Milani P, Merlini G, et al. Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis. *J Clin Oncol.* 2023; 41(7): 1393-403. Doi: 10.1200/JCO.22.00643
24. Kourelis T V, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. *J Clin Oncol.* 2013; 31(34): 4319-24. Doi: 10.1200/JCO.2013.50.8499
25. Vaxman I, Sidiqi MH, Al Saleh AS, Kumar S, Muchtar E, Dispenzieri A, et al. Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. *Bone Marrow Transplant.* 2021; 56(4): 928-35. Doi: 10.1038/s41409-020-01136-2
26. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. *Am J Hematol.* 2005; 79(4): 319-28. Doi: 10.1002/ajh.20381
27. Comenzo RL, Reece D, Palladini G, Seldin D, Sancherawala V, Landau H, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. *Leukemia.* 2012; 26(11): 2317-25. Doi: 10.1038/leu.2012.100
28. Posadas-Martinez ML, Aguirre MA, Brulc E, Saez MS, Sorroche P, Machnicki G, et al. Treatment patterns

- and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina. *PLoS One*. 2022; 17(10): e0274578. Doi: 10.1371/journal.pone.0274578
29. Peña C, González JT, López-Vidal H, Donoso J, Contreras C, Vergara CG, et al. AL amyloidosis in the Chilean public health system: a pending debt. Multicenter study of the Chilean Monoclonal Gammopathies Cooperative Group. *Rev Med Chil*. 2019; 147(10): 1239-46. Doi: 10.4067/s0034-98872019001001239
30. Michael M, Kastiris E, Delimpassi S, Michalis E, Repoussis P, Kyrtonis MC, et al. Clinical Characteristics and Outcome of Primary Systemic Light-Chain Amyloidosis in Greece. *Clin Lymphoma Myeloma Leuk*. 2010; 10(1): 56-61. Doi: 10.3816/CLML.2010.n.006
31. He D, Guan F, Hu M, Zheng G, He J, Han X, et al. The clinical characteristics and prognosis of chinese patients with light-chain amyloidosis: a retrospective multicenter analysis. *Indian J Hematol Blood Transfusion*. 2022; 38(3): 444-53. Doi: 10.1007/s12288-021-01469-y
32. Muchtar E, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, et al. A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. *Mayo Clin Proc*. 2019; 94(3): 472-483. Doi: 10.1016/j.mayocp.2018.08.006
33. Zhao Q, Li F, Song P, Zhou X, Wang L, Yu Y, et al. Clinical Characteristics and Treatment Outcome of Chinese Patients With Systemic Amyloid Light-Chain Amyloidosis: A Retrospective Single-Center Analysis. *Clin Lymphoma Myeloma Leuk*. 2016; 16(2): 104-10. Doi: 10.1016/j.clml.2015.11.001
34. Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchowala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. *Blood*. 2019; 133(3): 215-23. Doi: 10.1182/blood-2018-06-858951
35. Palladini G, Milani P, Merlini G. Predicting survival in light chain amyloidosis. *Haematologica*. 2019; 104(7): 1294-6. Doi: 10.3324/haematol.2019.218859
36. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. *J Clin Oncol*. 2012; 30(9): 989-95. Doi: 10.1200/JCO.2011.38.5724
37. Gillmore JD, Wechalekar A, Bird J, Cavenagh J, Hawkins S, Kazmi M, et al. Guidelines on the diagnosis and investigation of AL amyloidosis. *Br J Haematol*. 2015; 168(2): 207-18. Doi: 10.1111/bjh.13156
38. Foli A, Palladini G, Caporali R, Verga L, Morbini P, Obici L, et al. The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. *Amyloid*. 2011; 18(sup1): 80-2. Doi: 10.3109/13506129.2011.574354029
39. Basset M, Milani P, Nuvolone M, Benigna F, Rodigari L, Foli A, et al. Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis. *Blood Adv*. 2020; 4(17): 4175-9. Doi: 10.1182/bloodadvances.2020002219